Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Chief Financial Officer
Effective September 7, 2022, CareDx, Inc. (the "Company") appointed Abhishek
Jain, age 46, as the Company's Chief Financial Officer. Mr. Jain will retain the
duties of the Company's principal financial officer and principal accounting
officer until such time as his successor is appointed, or until his earlier
resignation or removal. There are no reportable family relationships or related
party transactions (as defined in Item 404(a) of Regulation S-K) involving the
Company and Mr. Jain.
Mr. Jain has served as the Company's Interim Chief Financial Officer since May
2022. Prior to that, since joining the Company in August 2021, Mr. Jain had
served as the Company's Vice President, Corporate Controller, where he was
responsible for global accounting functions and SEC filings. During that time,
he worked closely with the Company's Audit Committee of its Board of Directors,
FP&A team and business partners. Prior to joining the Company, Mr. Jain spent
approximately 20 years at Agilent Technologies, Inc., in a number of progressing
finance positions and customer-facing roles, including his last role where he
helped drive above-market growth for orders of an approximately $5 billion
business. Mr. Jain has extensive knowledge in driving channel strategy,
expanding margins, scaling operations, and leading global teams. Mr. Jain is a
member of the Institute of Chartered Accountants of India.
In connection with Mr. Jain's appointment as Chief Financial Officer, the
Compensation Committee of the Company's Board of Directors (the "Committee")
approved an increase in Mr. Jain's annualized salary from $305,000 to $375,000,
and an increase in his target annual performance bonus from 35% to 60% of his
annual base salary. His salary and performance bonus percentage may be adjusted
in the future at the discretion of the Committee. In connection with his
appointment, on September 7, 2022, Mr. Jain was granted an option to purchase
60,000 shares of the Company's common stock (the "Jain Option") and 22,150
restricted stock units ("Jain RSUs") under the Company's 2014 Equity Incentive
Plan, as amended (the "2014 Plan"). The Jain Option will vest, subject to
Mr. Jain's continued employment with the Company, 1/4th on the one-year
anniversary of the grant date, and 1/48th of the total number of shares subject
to the Jain Option will vest each month thereafter. The Jain RSUs will vest,
subject to Mr. Jain's continued employment with the Company, 1/4th on each
one-year anniversary of the grant date.
Chief Administrative & Legal Officer and Secretary
Effective September 7, 2022, the Company appointed Abraham Ronai, age 49, as the
Company's Chief Administrative & Legal Officer and Secretary. There are no
reportable family relationships or related party transactions (as defined in
Item 404(a) of Regulation S-K) involving the Company and Mr. Ronai.
Mr. Ronai has served as the Company's General Counsel since September 2021.
Prior to joining the Company, Mr. Ronai spent 11 years at Getinge AB, a global
medical technology company, holding various leadership roles, including Global
General Counsel. Prior to Getinge, Mr. Ronai worked at two well-respected law
firms in Manhattan and at Datascope Corp., a Nasdaq-listed medical device
company. Mr. Ronai also served as a professor for patent litigation at Concord
Law School. He earned his Bachelor of Science in Mechanical Engineering from
Cornell University and his Juris Doctor from the Benjamin N. Cardozo School of
Law at Yeshiva University. Mr. Ronai is Registered In-House Counsel in
California, and admitted to practice law in New York and New Jersey.
In connection with Mr. Ronai's appointment as Chief Administrative & Legal
Officer and Secretary, the Committee approved an increase in Mr. Ronai's target
annual performance bonus from 50% to 60% of his annual base salary. Mr. Ronai's
annualized salary will remain unchanged at its previous level of $388,125. His
salary and performance bonus percentage may be adjusted in the future at the
discretion of the Committee. In connection with his appointment, on September 7,
2022, Mr. Ronai was granted an option to purchase 36,000 shares of the Company's
common stock (the "Ronai Option") and 12,000 restricted stock units ("Ronai
RSUs") under the 2014 Plan. The Ronai Option will vest, subject to Mr. Ronai's
continued employment with the Company, 1/4th on the one-year anniversary of the
grant date, and 1/48th of the total number of shares subject to the Ronai Option
will vest each month thereafter. The Ronai RSUs will vest, subject to
Mr. Ronai's continued employment with the Company, 1/4th on each one-year
anniversary of the grant date.
President of Testing Services
Effective September 7, 2022, Alexander L. Johnson transitioned from his role as
Chief Business Officer and Head of Testing Services to the role of President of
Patient and Testing Services. Mr. Johnson will remain an executive officer of
the Company and an officer for purposes of Section 16 of the Securities Exchange
Act of 1934, as amended.
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
104 Cover Page Interactive Data File, formatted in Inline Extensible
Business Reporting Language (iXBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses